334 related articles for article (PubMed ID: 20708812)
21. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Flatt PR; Bailey CJ; Green BD
Front Biosci; 2008 May; 13():3648-60. PubMed ID: 18508462
[TBL] [Abstract][Full Text] [Related]
22. Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Tibaldi JM
Adv Ther; 2014 Mar; 31(3):289-317. PubMed ID: 24535623
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
25. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
[TBL] [Abstract][Full Text] [Related]
26. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
28. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Ahrén B
Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
[TBL] [Abstract][Full Text] [Related]
29. DPP4 inhibitors: a new approach in diabetes treatment.
Doupis J; Veves A
Adv Ther; 2008 Jul; 25(7):627-43. PubMed ID: 18641927
[TBL] [Abstract][Full Text] [Related]
30. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic analysis of DPP-4 inhibitors.
Teramachi H; Ohta H; Tachi T; Toyoshima M; Mizui T; Goto C; Tsuchiya T
Pharmazie; 2013 Nov; 68(11):909-15. PubMed ID: 24380242
[TBL] [Abstract][Full Text] [Related]
32. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Rizzo MR; Barbieri M; Marfella R; Paolisso G
Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
[TBL] [Abstract][Full Text] [Related]
33. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
34. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
35. [New concepts in the treatment of type 2 diabetes].
Meier JJ; Schmidt WE; Klein HH
Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
[TBL] [Abstract][Full Text] [Related]
36. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
38. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
[TBL] [Abstract][Full Text] [Related]
39. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Wani JH; John-Kalarickal J; Fonseca VA
Cardiol Clin; 2008 Nov; 26(4):639-48. PubMed ID: 18929237
[TBL] [Abstract][Full Text] [Related]
40. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
